<?xml version='1.0' encoding='utf-8'?>
<document id="16891850"><sentence text="[Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors]." /><sentence text="Options for antiretroviral therapy in patients infected with HIV continue to expand as new drugs are integrated into treatment regimens" /><sentence text=" Nucleoside/nucleotide reverse transcriptase inhibitors (Nt/NRTIs) remain the backbone of highly active antiretroviral therapy (HAART)" /><sentence text=" Although this is the oldest class of antiretrovirals, pharmacokinetic and pharmacodynamic properties have been less studied as compare to protease inhibotors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs)" /><sentence text=" The aim of this article is to review the current status of clinical pharmacology onf Nt/NRTIs, highlighting the issues with clinical interest" /><sentence text=" Therefore, implications of intracellular pharmacokinetics on dosing schedule, potential for drug-drug interaction and pharmacodynamics is discussed" /><sentence text="" /></document>